Brief: Egetis Therapeutics Q1 Adj. EPS at SEK -0.3
26/04/2023 06:09
Apr 26 (Reuters) - Egetis Therapeutics Q1 revenue SEK 6.8 million. * Q1 adjusted EPS SEK -0.3
Recent news on Egetis Therapeutics AB (publ)
See all newsBrief: Egetis Announces Grant Of Patent For MCT8 Deficiency Composition In U.S.
Swedisg drugmaker Egetis's Q1 revenue rises 9% on Emcitate sales in Europe
Brief: Egetis Therapeutics Q1 Loss SEK 94.5 Mln
Brief: Egetis Plans Directed Share Issue Raising SEK 350 Million
Brief: Egetis Therapeutics Appoints Tiago Nunes As CMO Effective May 1